NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
Clinical Trials
20 trialsNCT01468922 2022-07-01
Pazopanib and ARQ 197 for Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01636908 2021-04-15
ICK
Amsterdam UMC, location VUmc
Phase NA Completed
NCT01235962 2020-11-23
PROTECT
Novartis
Phase 3 Completed
NCT02138526 2020-10-19
DIET
Radboud University Medical Center
Phase 1 Completed
NCT01466972 2020-07-08
Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib
University of California, San Francisco
Phase 2 Completed
NCT00674024 2019-11-20
Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00387205 2019-03-06
Study To Assess Long Term Safety Of Pazopanib
Novartis
Phase 1 Completed
NCT00861029 2017-11-14
VEG111485: A QTc Study of Pazopanib
GlaxoSmithKline
Phase 1 Completed
NCT00516672 2017-11-13
Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00722293 2017-11-13
A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00992121 2017-11-13
An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma
GlaxoSmithKline
Phase 1 Completed
NCT01130623 2017-07-02
A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT01108055 2017-06-09
Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
Stanford University
Phase 2 Completed
NCT01064310 2017-04-17
PISCES
Novartis
Phase 3 Completed
NCT01262014 2016-08-11
Clinical Trial Investigating Pazopanib in Patients With Platinum-resistant Advanced Ovarian Cancer
Grupo Español de Investigación en Cáncer de Ovario
Phase 2 Completed
NCT02307474 2016-03-03
A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer
Case Comprehensive Cancer Center
Phase NA Withdrawn
NCT00430781 2015-05-08
Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer
GlaxoSmithKline
Phase 2 Completed
NCT01205230 2012-05-22
VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK
GlaxoSmithKline
Phase 4 Completed
NCT00561795 2012-03-22
Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors
GlaxoSmithKline
Phase 2 Completed